These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8283648)

  • 1. [DNA topoisomerase inhibitor].
    Hino M; Niitani H
    Nihon Rinsho; 1993 Dec; 51(12):3291-300. PubMed ID: 8283648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumor agents targeting mammalian topoisomerases].
    Nakano H
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1550-5. PubMed ID: 1651681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
    Tanabe K; Ikegami Y; Ishida R; Andoh T
    Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity.
    Swift LP; Cutts SM; Nudelman A; Levovich I; Rephaeli A; Phillips DR
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):739-49. PubMed ID: 17594094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
    Nitiss JL
    Curr Opin Investig Drugs; 2002 Oct; 3(10):1512-6. PubMed ID: 12431029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Beck WT; Danks MK
    Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
    Emerson DL; Besterman JM; Brown HR; Evans MG; Leitner PP; Luzzio MJ; Shaffer JE; Sternbach DD; Uehling D; Vuong A
    Cancer Res; 1995 Feb; 55(3):603-9. PubMed ID: 7834631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topoisomerases, new targets in cancer chemotherapy.
    Zijlstra JG; de Jong S; de Vries EG; Mulder NH
    Med Oncol Tumor Pharmacother; 1990; 7(1):11-8. PubMed ID: 2160032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
    Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
    Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3-Arylisoquinolines as novel topoisomerase I inhibitors.
    Khadka DB; Cho WJ
    Bioorg Med Chem; 2011 Jan; 19(2):724-34. PubMed ID: 21095131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
    Sinha BK
    Drugs; 1995 Jan; 49(1):11-9. PubMed ID: 7705211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs.
    Lansiaux A; Léonce S; Kraus-Berthier L; Bal-Mahieu C; Mazinghien R; Didier S; David-Cordonnier MH; Hautefaye P; Lavielle G; Bailly C; Hickman JA; Pierré A
    Mol Pharmacol; 2007 Aug; 72(2):311-9. PubMed ID: 17494837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and intracellular inhibition of topoisomerase II by the antitumor agent merbarone.
    Drake FH; Hofmann GA; Mong SM; Bartus JO; Hertzberg RP; Johnson RK; Mattern MR; Mirabelli CK
    Cancer Res; 1989 May; 49(10):2578-83. PubMed ID: 2540903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 1'-substituent on the anilino ring of the antitumor drug amsacrine is a critical element for topoisomerase II inhibition and cytotoxicity.
    Rene B; Fosse P; Khelifa T; Jacquemin-Sablon A; Bailly C
    Mol Pharmacol; 1996 Feb; 49(2):343-50. PubMed ID: 8632768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Topoisomerase inhibitors developing in Japan].
    Furue H
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):42-9. PubMed ID: 8422186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
    Fossé P; Charra M; Paoletti C; Saucier JM; René B
    Bull Cancer; 1994 Mar; 81(3):194-202. PubMed ID: 7894127
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NK314, a novel topoisomerase II inhibitor, induces rapid DNA double-strand breaks and exhibits superior antitumor effects against tumors resistant to other topoisomerase II inhibitors.
    Onda T; Toyoda E; Miyazaki O; Seno C; Kagaya S; Okamoto K; Nishikawa K
    Cancer Lett; 2008 Jan; 259(1):99-110. PubMed ID: 17998154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.